Denali Therapeutics Stock Is Sliding After The Bell: Here's Why

Denali Therapeutics Inc (NASDAQ:DNLI) shares are moving lower in Thursday’s after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.

What Happened: After the market close on Thursday, Denali said strategic partner Sanofi SA (NASDAQ:SNY) informed the company that its K2 Phase 2 study evaluating oditrasertib on serum neurofilament light chain levels in participants with multiple sclerosis was discontinued because it failed to meet the primary and key secondary endpoints.

In the company’s earnings release from August, Denali ...

Full story available on Benzinga.com